During November, the number of shares and votes in Alligator Bioscience AB has increased due to the new issue of shares that was made in connection with the listing of the company’s shares on Nasdaq Stockholm. As of November 30, 2016, the number of shares and votes in Alligator Bioscience AB amounts to 70,013,615.
Alligator is a research-based biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company is headquartered in Lund, Sweden, and had 35 employees per September 30, 2016. The Company is primarily active in the early stages of drug development, from the idea stage to clinical phase IIa studies, and Alligator’s product portolio primarily consist of the product candidates ADC-1013, ATOR-1015 and ATOR-1016. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. For more information, visit http://www.alligatorbioscience.com.
For further information, please contact:
Per Norlén, CEO
Telephone: +46 46 2864280
Rein Piir, VP Investor Relations
Telephone: +46 708 537292
The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.45 CET on November 30, 2016.